Alvotech, an independent sister company of Alvogen, a powerful new player in the field of biopharmaceuticals, has announced plans to invest $250 million in the development and manufacturing of a portfolio of biosimilar monoclonal antibodies.
Highly experienced management team with a proven track record of achieving high growth and profitability
The Alvogen family is committed to making the world a better place for children and our programs involve everyone at Alvogen.
Alvogen is a multinational, privately-owned pharmaceuticals company, focused on complex generic pharmaceutical products.
Download the latest company presentation and learn more about our global business, management and growth strategy.
Download center for company logos, high-resolution images, presentations, fact sheets and more.
Get an insiders view of the company through blogs from our CEO, Robert Wessman.
Would you like to learn more about Alvogen, speak with our management or do you have an idea for partnership or future collaboration? We would like to hear from you.
Halldor Kristmannsson Organizational Development Global Communications & Branding
Phone (354) email@example.com Connect on LinkedIn